Bepotastine besilate

Drug Profile

Bepotastine besilate

Alternative Names: Bepotastine; Bepreve; Betotastine; Betotastine besilate; Talion; Talion OD Tablets; TAU-284

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ube Industries
  • Developer ISTA Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Ube Industries
  • Class Antiallergics; Antiasthmatics; Antihistamines; Antipruritics; Butyric acids; Chlorobenzenes; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Perennial allergic rhinitis; Pruritus; Urticaria
  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 14 Aug 2015 No recent reports on development identified - Phase-II for Seasonal allergic rhinitis in USA (Intranasal)
  • 26 May 2015 Registered for Perennial allergic rhinitis (In adolescents, In children) in Japan (PO)
  • 01 Nov 2013 Mitsubishi Tanabe Pharma completes a phase III trial in Perennial allergic rhinitis (in paediatric patients) in Japan (NCT01900054)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top